Conferences

ecancer travels so that you don't have to. Explore the latest conference coverage in global oncology and find out where we are going next.
Bookmark and Share

AACR 2019

29 Mar - 3 Apr 2019
Georgia World Congress Center, Atlanta, United States of America
Accelerated tumour growth due to immunotherapy: Fact or fiction?
Dr Marina Garassino - National Tumor Institute, Milan, Italy
Accelerated tumour growth due to immunotherapy: Fact or fiction? ( Dr Marina Garassino - National Tumor Institute, Milan, Italy )
18 Apr 2019
Biomarkers of systemic inflammation linked to reduced clinical activity of atezo...
Luciana Molinero - Genentech, San Francisco, USA
Biomarkers of systemic inflammation linked to reduced clinical activity of atezolizumab monotherapy in metastatic TNBC ( Luciana Molinero - Genentech, San Francisco, USA )
18 Apr 2019
KEYNOTE-028 and KEYNOTE-158: Pembrolizumab as treatment for advanced SCLC after ...
Prof Hyun Cheol Chung - Yonsei University, Seoul, South Korea
KEYNOTE-028 and KEYNOTE-158: Pembrolizumab as treatment for advanced SCLC after two or more lines of prior therapy ( Prof Hyun Cheol Chung - Yonsei University, Seoul, South Korea )
15 Apr 2019
5' UTR mutations in prostate cancer
Dr Yiting Lim, Fred Hutchinson Cancer Research Center, Seattle, USA
5' UTR mutations in prostate cancer ( Dr Yiting Lim, Fred Hutchinson Cancer Research Center, Seattle, USA )
15 Apr 2019
Cancer preventive vaccine used in mouse model of Lynch syndrome
Prof Steven Lipkin - Weill Cornell Medical College, New York, USA
Cancer preventive vaccine used in mouse model of Lynch syndrome ( Prof Steven Lipkin - Weill Cornell Medical College, New York, USA )
15 Apr 2019
ADMIRAL: Gilteritinib as treatment for patients with relapsed or refractory acut...
Prof Alexander Perl - University of Pennsylvania, Philadelphia, USA
ADMIRAL: Gilteritinib as treatment for patients with relapsed or refractory acute myeloid leukaemia ( Prof Alexander Perl - University of Pennsylvania, Philadelphia, USA )
15 Apr 2019
Immunomodulatory effects of PARP inhibition in BRCA1-deficient triple-negative b...
Dr Constantia Pantelidou - Dana Farber Cancer Institute, Boston, USA
Immunomodulatory effects of PARP inhibition in BRCA1-deficient triple-negative breast cancer ( Dr Constantia Pantelidou - Dana Farber Cancer Institute, Boston, USA )
15 Apr 2019
Talimogene laherparepvec combined with neoadjuvant chemotherapy for non-metastat...
Dr Hatem Soliman - Moffitt Cancer Centre, Tampa, USA
Talimogene laherparepvec combined with neoadjuvant chemotherapy for non-metastatic triple negative breast cancer ( Dr Hatem Soliman - Moffitt Cancer Centre, Tampa, USA )
15 Apr 2019
Efficacy and immune correlates of the SRA737 plus LDG regimen in combination wit...
Dr Triparna Sen - MD Anderson Cancer Center, Houston, Texas
Efficacy and immune correlates of the SRA737 plus LDG regimen in combination with anti-PD-L1 in an SCLC model ( Dr Triparna Sen - MD Anderson Cancer Center, Houston, Texas )
15 Apr 2019
Lymphodepleting chemotherapy in order to safely improve the expansion of HER2-CA...
Prof Shoba Navai - Baylor College of Medicine, Houston, USA
Lymphodepleting chemotherapy in order to safely improve the expansion of HER2-CAR T cells in patients with advanced sarcomas ( Prof Shoba Navai - Baylor College of Medicine, Houston, USA )
15 Apr 2019
TATTON: Osimertinib plus savolitinib for patients with EGFR-mutant, MET-amplifie...
Prof Lecia Sequist - Massachusetts General Hospital, Boston, USA
TATTON: Osimertinib plus savolitinib for patients with EGFR-mutant, MET-amplified NSCLC after progression on EGFR-TKI ( Prof Lecia Sequist - Massachusetts General Hospital, Boston, USA )
15 Apr 2019
Evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1, in...
Dr James Gulley - National Cancer Institute, Bethesda, USA
Evaluation of M7824, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with HPV-associated malignancies ( Dr James Gulley - National Cancer Institute, Bethesda, USA )
15 Apr 2019
Using T cell engineering plus triple checkpoint blockade to enhance the efficacy...
Dr Kristin Anderson - Fred Hutchinson Cancer Research Center, Seattle, USA
Using T cell engineering plus triple checkpoint blockade to enhance the efficacy of adoptive immunotherapy in ovarian cancer ( Dr Kristin Anderson - Fred Hutchinson Cancer Research Center, Seattle, USA )
15 Apr 2019
The hereditary link between African-Americans and people in Africa and its relat...
Prof John Carpten - Keck School of Medicine, Los Angeles, USA
The hereditary link between African-Americans and people in Africa and its relationship to cancer incidence and outcomes ( Prof John Carpten - Keck School of Medicine, Los Angeles, USA )
15 Apr 2019
Combining the SLP vaccine with chemo-immunotherapy in order to increase the HPV-...
Prof Kees Melief - Leiden University Medical Center, Leiden, Netherlands
Combining the SLP vaccine with chemo-immunotherapy in order to increase the HPV-specific T-cell response in cervical cancer ( Prof Kees Melief - Leiden University Medical Center, Leiden, Netherlands )
15 Apr 2019
Digitising clinical assessment and using it for evidence-based prediction of out...
Prof Jorge Nieva - Keck School of Medicine, Los Angeles, USA
Digitising clinical assessment and using it for evidence-based prediction of outcomes ( Prof Jorge Nieva - Keck School of Medicine, Los Angeles, USA )
15 Apr 2019
African Access Initiative: Improving patient outcomes in Africa
Jennifer Dent - BIO Ventures for Global Health, Seattle, USA
African Access Initiative: Improving patient outcomes in Africa ( Jennifer Dent - BIO Ventures for Global Health, Seattle, USA )
15 Apr 2019
Umbralisib as a monotherapy in patients with relapsed/refractory marginal zone l...
Prof Nathan Fowler - MD Anderson Cancer Center, Houston, USA
Umbralisib as a monotherapy in patients with relapsed/refractory marginal zone lymphoma ( Prof Nathan Fowler - MD Anderson Cancer Center, Houston, USA )
15 Apr 2019
Risk factors for prostate cancer in men of African descent
Dr Faruk Mohammed - Ahmadu Bello University, Zaria, Nigeria
Risk factors for prostate cancer in men of African descent ( Dr Faruk Mohammed - Ahmadu Bello University, Zaria, Nigeria )
15 Apr 2019
Using regionally delivered autologous mesothelin-targeted CAR T cells in the tre...
Dr Prasad Adusumilli - Memorial Sloan Kettering Cancer Center, New York, USA
Using regionally delivered autologous mesothelin-targeted CAR T cells in the treatment of malignant pleural disease ( Dr Prasad Adusumilli - Memorial Sloan Kettering Cancer Center, New York, USA )
15 Apr 2019
Social media as a tool for scientists
Bims Odedina - University of South Florida, Tampa, USA
Social media as a tool for scientists ( Bims Odedina - University of South Florida, Tampa, USA )
15 Apr 2019
Tumour shrinkage with ipilimumab plus nivolumab in patients with neuroendocrine ...
Prof Sandip Patel - UC San Diego, San Diego, USA
Tumour shrinkage with ipilimumab plus nivolumab in patients with neuroendocrine carcinoma ( Prof Sandip Patel - UC San Diego, San Diego, USA )
15 Apr 2019
Importance of capacity development for African researchers
Dr Soloman Rotimi - Covenant University, Ota, Nigeria
Importance of capacity development for African researchers ( Dr Soloman Rotimi - Covenant University, Ota, Nigeria )
15 Apr 2019
Increased stroke risk in childhood cancer survivors
Dr Yadav Sapkota - St. Jude Children's Research Hospital, Memphis, USA
Increased stroke risk in childhood cancer survivors ( Dr Yadav Sapkota - St. Jude Children's Research Hospital, Memphis, USA )
15 Apr 2019
KEYNOTE 189: Targeting NSCLC patients with brain and liver metastases
Dr Marina Garassino - National Tumor Institute, Milan, Italy
KEYNOTE 189: Targeting NSCLC patients with brain and liver metastases ( Dr Marina Garassino - National Tumor Institute, Milan, Italy )
15 Apr 2019
Trends in breast cancer incidence and risk
Prof Rowan Chlebowski - City of Hope National Medical Center, Duarte, USA
Trends in breast cancer incidence and risk ( Prof Rowan Chlebowski - City of Hope National Medical Center, Duarte, USA )
15 Apr 2019
MYSTIC: Developing biomarkers for metastatic NSCLC
Prof Solange Peters - Centre Hospitalier Universitaire Vaudois, Lausanne, Switze...
MYSTIC: Developing biomarkers for metastatic NSCLC ( Prof Solange Peters - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland )
11 Apr 2019
TATTON: Updated results for patients with EGFR-mutant NSCLC
Prof Leica Sequist - Massachusetts General Hospital, Boston, USA
TATTON: Updated results for patients with EGFR-mutant NSCLC ( Prof Leica Sequist - Massachusetts General Hospital, Boston, USA )
11 Apr 2019
Mesothelin-targeted CAR T-cell therapy safe, shows early promise in patients wit...
Dr Prasad Adusumilli - Memorial Sloan Kettering Cancer Center, New York, USA
Mesothelin-targeted CAR T-cell therapy safe, shows early promise in patients with advanced solid tumours ( Dr Prasad Adusumilli - Memorial Sloan Kettering Cancer Center, New York, USA )
11 Apr 2019
Immune checkpoint inhibitor combination efficacious for patients with high-grade...
Prof Sandip Patel - UC San Diego, San Diego, USA
Immune checkpoint inhibitor combination efficacious for patients with high-grade neuroendocrine carcinoma ( Prof Sandip Patel - UC San Diego, San Diego, USA )
11 Apr 2019
HER2-targeted CAR T-cell therapy safe and showing promising antitumour activity ...
Prof Shoba Navai - Baylor College of Medicine, Houston, USA
HER2-targeted CAR T-cell therapy safe and showing promising antitumour activity in patients with advanced sarcoma ( Prof Shoba Navai - Baylor College of Medicine, Houston, USA )
11 Apr 2019
Cancer preventive vaccine showed promising results in preclinical model of Lynch...
Prof Steven Lipkin - Weill Cornell Medical College, New York, USA
Cancer preventive vaccine showed promising results in preclinical model of Lynch syndrome ( Prof Steven Lipkin - Weill Cornell Medical College, New York, USA )
11 Apr 2019
Umbralisib shows early promise for patients with marginal zone lymphoma
Prof Nathan Fowler - MD Anderson Cancer Center, Houston, USA
Umbralisib shows early promise for patients with marginal zone lymphoma ( Prof Nathan Fowler - MD Anderson Cancer Center, Houston, USA )
11 Apr 2019
KEYNOTE trials show pembrolizumab benefited patients with advanced small cell lu...
Prof Hyun Cheol Chung - Yonsei University, Seoul, South Korea
KEYNOTE trials show pembrolizumab benefited patients with advanced small cell lung cancer ( Prof Hyun Cheol Chung - Yonsei University, Seoul, South Korea )
11 Apr 2019
Gilteritinib improved survival for patients with acute myeloid leukaemia
Prof Alexander Perl - University of Pennsylvania, Philadelphia, USA
Gilteritinib improved survival for patients with acute myeloid leukaemia ( Prof Alexander Perl - University of Pennsylvania, Philadelphia, USA )
11 Apr 2019
Personalised research for cancer care in Africa
Prof Folakemi Odedina - University of Florida, Gainesville, USA
Personalised research for cancer care in Africa ( Prof Folakemi Odedina - University of Florida, Gainesville, USA )
10 Apr 2019
Improving cancer care in Nigeria
Prof Ifeoma Okoye - University of Nigeria, Nsukka, Nigeria
Improving cancer care in Nigeria ( Prof Ifeoma Okoye - University of Nigeria, Nsukka, Nigeria )
10 Apr 2019
Clinical trials in Africa: Bench to bedside
Prof Ifeoma Okoye - University of Nigeria, Nsukka, Nigeria
Clinical trials in Africa: Bench to bedside ( Prof Ifeoma Okoye - University of Nigeria, Nsukka, Nigeria )
10 Apr 2019
Inequities in global healthcare
Ms Dicey Scroggins - International Gynecologic Cancer Society, Austin, USA
Inequities in global healthcare ( Ms Dicey Scroggins - International Gynecologic Cancer Society, Austin, USA )
10 Apr 2019